Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium

Journal of Thoracic Disease

Volumn 2, Issue 3, 2010, Pages 160-170

  Papademetriou, Konstantinos ^a   Ardavanis, Alexandros ^b   Kountourakis, Panteleimon ^a  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Biological therapy; Locally advanced breast cancer; Multimodality approach; Neoadjuvant chemotherapy

Indexed keywords

EID: 83655166303     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
2. National Cancer Institute, DCCPS, Surveilance Research Program Cancer Statistics Branch (2001). SEER Program Public Use Data Tapes 1973-1998.
3. Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, et al. Pathological complete response to chemotherapy is related to hormone receptor status [abstract]. Breast Cancer Res Treat 2003;85:2.
4. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5year clinical outcome? Ann Oncol 2003;14:406-13.
5. Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, et al. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2010;10:230-7.
6. Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, et al. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. J Cancer Res Clin Oncol 2010 Apr 13. [Epub ahead of print]
7. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
8. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
9. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990;66:1387-91.
10. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol 1992;10:1014-24.
11. Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol 2009;19:222-8.
12. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010;15:101:283-91.
13. Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer 2003;4:s10-9.
14. Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer 2010;116:s2821-8.
15. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52:2127-37.
16. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;26:786-90.
17. Cristofanilli M, Valero V, Buzdar AU, Shu-Wan Kau, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 2007;110:1436-44.
18. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-9.
19. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst 2001;30:96-102.
20. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006;24:2019-27.
21. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
22. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84.
23. Gazet JC, Ford HT, Gray R, McConkey C, Sutcliffe R, Quilliam J, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001;12:685-91.
24. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
25. Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991;27:1668-71.
26. Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151-6.
27. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst2005;97:188-94.
28. Dan Costa S, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010;28:83-91.
29. Hutcheon AW, Heys SD, Sarkar TK. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003;79:s19-24.
30. Hutcheon AW, Heys SD, Miller ID. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: A randomised controlled trial [abstract]. Breast Cancer Res Treat 2001;69:298.
31. Hutcheon AW, Heys SD, Sarkar TK. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial [abstract]. Breast Cancer Res Treat 2003;82:s9.
32. Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo- Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988-95.
33. Gradishar WJ, Wedam SB, Jahanzeb M, Erban J, Limentani SA, Tsai KT, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005;16:1297-304.
34. Untch M, Konecny G, Ditsch N. Dose dense sequential epirubicin paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol 2002;21:a133.
35. Jackisch C, von Minckwitz G, Raab G, Schuette M, Blohmer JU, Hilfrich J, et al. Primary endpoint analysis of the GEPAR-DUO study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (T2-3, N0-2, M0) [abstract]. Breast Cancer Res Treat 2002;76:s50.
36. Limentani SA, Brufsky AM, Erban J K, Jahanzeb M, Lewis D Blumenthal et al. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support [abstract]. Proc Am Soc Clin Oncol 2003;22:33.
37. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010;21:961-7.
38. von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999;17:1999-2005.
39. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999;17:3033-7.
40. Malhotra V, Dorr VJ, Lyss AP, Anderson CM, Westgate S, Reynolds M, et al. Neoadjuvant and adjuvant chemotherapy (CT) with doxorubicin and docetaxel (DD) with surgery and radiation in locally advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2001;2:b6.
41. Valero V, Esteva FJ, Sahin AA, Booser DJ, Strom EA, Esparza-Guerra LT, et al. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy ± tamoxifen in locally advanced breast cancer [abstract]. Breast Cancer Res Treat 2000;64:69.
42. Bouzid K, Vinholes J, Salas F, Mickiewicz E, Valdivia S, Ostapenko V, et al. A Phase III trial of Taxotere and doxorubicin (AT) vs 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: An interim analysis [abstract]. Eur J Cancer 2001;37:s167.
43. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colonystimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001;19:3506-15.
44. Bines J, Vinholes J, Del Giglio A, Vasconcelos A, Cabral C, Gusmao C, et al. Neo-adjuvant chemotherapy with weekly docetaxel (taxotere) in poor prognosis locally-advanced breast cancer (LABC) [abstract]. Breast Cancer Res Treat 2002;76:s54.
45. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and fluorouracil with dose intensified epirubicin and cyclophosphamide+ filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-50.
46. Ellis GK, Green SJ, Russell CA, Royce ME, Perez EA, Livingston RB. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as Neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:s12.
47. Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist 2006;11:563-73.
48. Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, et al. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol 2009:27:571-7.
49. Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, et al. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer 2009;9:166-72.
50. Jinno H, Sakata M, Hayashida T, Takahashi M, Mukai M, Ikeda T, et al. A phase II trial of capecitabine and docetaxel followed by 5-FU/epirubicin /cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 2010;21:1262-6.
51. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
52. Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-luorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81-6
53. Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperth 2010;26:514-21.
54. Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, et al. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clin Breast Cancer 2010;10:217-23.
55. Antón A, Ruiz A, Plazaola A, Calvo L, Seguí MA, Santaballa A, et al. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 2010 Jul 5. [Epub ahead of print]
56. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-62.
57. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG14. J Clin Oncol 2007;25:2012-8.
58. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicincyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-51.
59. Verrill MW, Ashley SE, Walsh GA, Ellis P, Sacks N, Gui G, et al. Pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy for operable breast cancer [abstract]. Breast Cancer Res Treat 1998;50:328.
60. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert F J, et al. Neoadjuvant chemotherapy in breast cancer: Enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
61. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294-302.
62. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9.
63. Hortobagyi GN, Blumenshein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, et al. Multimodal Treatment of Locoregionally Advanced Breast Cancer. Cancer 1983;51:763-76.
64. Ragaz J, Baird R, Rebbeck P, Goldie J, Coldman A, Spinelli J, et al. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 1985;56:719-24.
65. Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
66. Jacquillat C, Baillet F, Weil M, Auclerc G, Housset M, Auclerc M, et al. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 1988;61:1977-82.
67. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988;62:2507-16.
68. Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B Study. J Clin Oncol 1988;6:261-9.
69. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 1990;15:137-47.
70. Pierce LJ, Lippman M, Ben-Baruch N, Swain S, O'Shaughnessy J, Bader JL, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992;23:949-60.
71. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-9.
72. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gunterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
73. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-9.
74. Touboul E, Lefranc JP, Blondon J, Buffat L, Deniaud E, Belkacémi Y, et al. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3cm or locally advanced non-inflammatory breast cancer. Radiother Onocol 1997;42:219-29.
75. Brain E, Garrino C, Misset JL, Carbonero GI, ltzhaki M, Cvitkovic E, et al. Long-term prognostic and predictive factors in 107 stage 11/111 breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. British Journal of Cancer 1997;75:1360-7.
76. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: Eight year experience of the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
77. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
78. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, et al. High complete response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat 2000;62:237-44.
79. Cristofanilli M, Buzdar AU, Snelge N, Smith T, Wasaff B, Ibrahim N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775-82.
80. Van Praagh I, Amat S, Delva R, Leduc B, Mouret-Reynier MA, Lortholary A, et al. Induction chemotherapy in operable breast cancer by NET regimen: Multicentric phase II trial [abstract]. Proc Am Soc Clin Oncol 2001;20:a1889.
81. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
82. Jahanzeb M, Brufsky A, Erban J, Lewis D, Limentani S. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support [abstract]. J Clin Oncol 2005;23:s26.
83. Raefsky E, Castillo R, Lahiry A, Thompson DS, Hanson S, Meng C, et al. Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (NAB paclitaxel) and carboplatin in HER2 locally advanced breast cancer [abstract]. J Clin Oncol 2008;26:s37.
84. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol 2005;23:3676-85.
85. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
86. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024-31.
87. Spector NL, Blackwell K, Hurley J, Harris JL, Lombardi D, Bacus S, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatorybreast cancer (IBC): Clinical activity and biologic predictors of response [abstract]. J Clin Oncol 2006;24:502.
88. Cristofanilli M, Boussen H, Baselga J, Lluch A, Ben Ayed F, Friaha M, et al. A phase II combination study of lapatinib (TYKERB) and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract]. San Antonio Breast Cancer Symposium;General Session. Breast Cancer Res Treat 2006;100:s5.
89. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:s117-24.
90. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
91. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract]. J Clin Oncol 2008;26:s1088.
92. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract]. J Clin Oncol 2009;27:s42.
93. Ardavanis A, Doufexis D, Kountourakis P, Malliou S, Karagiannis A, Kardara E, et al. Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks. A retrospective case review study. BMC Cancer 2009;9:338.
94. Kountourakis P, Doufexis D, Maliou S, Karagiannis A, Kardara E, Margari C, et al. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer. Anticancer Res 2010;30:2969-71.
95. Overmoyer P, Silverman P, Leeming R, Shenk R, Lyons J, Ziats N, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer [abstract]. Breast cancer Res Treat 2004;88:s106.
96. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77.
97. Hurvitz SA, Bosserman LD, Leland-Jones B, Thirwell M, Allison MK, Barstis J, et al. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer [abstract]. J Clin Oncol 2008;26:562.
98. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009;35:1048-54.
99. Waintraub S E, Tuchman V. The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer [abstract]. J Clin Oncol 2009;27:s11524.
100. Yardley DA, Raefsky E, Castillo R, Lahiry A, LoCicero R, Thompson D, et al. Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives [abstract]. J Clin Oncol 2009;27:s15.
101. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2010 Jul 12. [Epub ahead of print]
102. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75.
103. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009;360:679-91.
104. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
105. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.